IL119647A - Crystalline modification v of the hydrochloride of (r)-(-)-2-{n-[4-(1,1-dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl}-chroman, its preparation and a pharmaceutical composition containing it - Google Patents

Crystalline modification v of the hydrochloride of (r)-(-)-2-{n-[4-(1,1-dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl}-chroman, its preparation and a pharmaceutical composition containing it

Info

Publication number
IL119647A
IL119647A IL11964796A IL11964796A IL119647A IL 119647 A IL119647 A IL 119647A IL 11964796 A IL11964796 A IL 11964796A IL 11964796 A IL11964796 A IL 11964796A IL 119647 A IL119647 A IL 119647A
Authority
IL
Israel
Prior art keywords
benzisothiazol
dioxido
chroman
aminomethyl
dihydro
Prior art date
Application number
IL11964796A
Other languages
English (en)
Other versions
IL119647A0 (en
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of IL119647A0 publication Critical patent/IL119647A0/xx
Publication of IL119647A publication Critical patent/IL119647A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
IL11964796A 1995-11-22 1996-11-19 Crystalline modification v of the hydrochloride of (r)-(-)-2-{n-[4-(1,1-dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl}-chroman, its preparation and a pharmaceutical composition containing it IL119647A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19543478A DE19543478A1 (de) 1995-11-22 1995-11-22 Kristallines Hydrochlorid von {(R)-(-)-2- N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-buytl]-aminomethyl}-chroman

Publications (2)

Publication Number Publication Date
IL119647A0 IL119647A0 (en) 1997-02-18
IL119647A true IL119647A (en) 1999-12-22

Family

ID=7778081

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11964796A IL119647A (en) 1995-11-22 1996-11-19 Crystalline modification v of the hydrochloride of (r)-(-)-2-{n-[4-(1,1-dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl}-chroman, its preparation and a pharmaceutical composition containing it

Country Status (32)

Country Link
US (1) US5830908A (no)
EP (1) EP0775704B1 (no)
JP (1) JPH09143180A (no)
KR (1) KR970027079A (no)
CN (1) CN1086703C (no)
AR (1) AR004961A1 (no)
AT (1) ATE201872T1 (no)
AU (1) AU712922B2 (no)
BR (1) BR9605646A (no)
CA (1) CA2190700A1 (no)
CZ (1) CZ289730B6 (no)
DE (2) DE19543478A1 (no)
DK (1) DK0775704T3 (no)
EE (1) EE9600183A (no)
ES (1) ES2159342T3 (no)
GR (1) GR3036505T3 (no)
HU (1) HUP9603237A3 (no)
IL (1) IL119647A (no)
MX (1) MX9605741A (no)
MY (1) MY132473A (no)
NO (1) NO307340B1 (no)
NZ (1) NZ299780A (no)
PL (1) PL317090A1 (no)
PT (1) PT775704E (no)
RU (1) RU2181723C2 (no)
SG (1) SG44989A1 (no)
SI (1) SI0775704T1 (no)
SK (1) SK150096A3 (no)
TR (1) TR199600930A2 (no)
TW (1) TW449595B (no)
UA (1) UA45338C2 (no)
ZA (1) ZA969753B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CA2810839A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CN101784278A (zh) * 2007-08-17 2010-07-21 贝林格尔.英格海姆国际有限公司 用于治疗fab-相关的疾病的嘌呤衍生物
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX370599B (es) * 2008-08-15 2019-12-18 Boehringer Ingelheim Int Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
CA2803504C (en) 2010-06-24 2022-08-30 Boehringer Ingelheim International Gmbh A combination for diabetes therapy comprising linagliptin and a long-acting insulin
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Dpp−4阻害薬の医学的使用
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300523A (en) * 1988-07-28 1994-04-05 Bayer Aktiengesellschaft Substituted aminomethyltetralins and their heterocyclic analogues
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
DE4138756A1 (de) * 1991-11-26 1993-05-27 Troponwerke Gmbh & Co Kg Kombination mit neuroprotektiver wirkung

Also Published As

Publication number Publication date
JPH09143180A (ja) 1997-06-03
DE19543478A1 (de) 1997-05-28
MY132473A (en) 2007-10-31
IL119647A0 (en) 1997-02-18
SG44989A1 (en) 1997-12-19
PT775704E (pt) 2001-09-28
MX9605741A (es) 1997-05-31
PL317090A1 (en) 1997-05-26
ES2159342T3 (es) 2001-10-01
DE59607040D1 (de) 2001-07-12
GR3036505T3 (en) 2001-11-30
HU9603237D0 (en) 1997-01-28
NO964950L (no) 1997-05-23
CN1086703C (zh) 2002-06-26
CN1152574A (zh) 1997-06-25
BR9605646A (pt) 1998-08-18
TR199600930A2 (tr) 1997-06-21
US5830908A (en) 1998-11-03
TW449595B (en) 2001-08-11
EE9600183A (et) 1997-06-16
UA45338C2 (uk) 2002-04-15
SI0775704T1 (en) 2001-08-31
ATE201872T1 (de) 2001-06-15
CZ289730B6 (cs) 2002-03-13
EP0775704A1 (de) 1997-05-28
AU7177296A (en) 1997-05-29
HUP9603237A2 (hu) 1998-01-28
NO964950D0 (no) 1996-11-21
CA2190700A1 (en) 1997-05-23
KR970027079A (ko) 1997-06-24
AU712922B2 (en) 1999-11-18
EP0775704B1 (de) 2001-06-06
RU2181723C2 (ru) 2002-04-27
CZ342896A3 (en) 1997-06-11
NZ299780A (en) 1998-09-24
AR004961A1 (es) 1999-04-07
NO307340B1 (no) 2000-03-20
HUP9603237A3 (en) 1998-12-28
DK0775704T3 (da) 2001-07-23
SK150096A3 (en) 1997-08-06
ZA969753B (en) 1997-03-25

Similar Documents

Publication Publication Date Title
IL119647A (en) Crystalline modification v of the hydrochloride of (r)-(-)-2-{n-[4-(1,1-dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl}-chroman, its preparation and a pharmaceutical composition containing it
HUT67023A (en) Monohydrate of 5-{2-[4-(1,2-benzisothiazol-3-yl)-1-pierazinyl]ethyl}-6-chloro-1,3-dihydro-2h-indole-5-one hydrochloride and pharmaceutical compositions containing that
HRP960558B1 (en) New crystalline modifications of cdch, processes for the preparation thereof and pharmaceutical compositions containing them
HUP9900881A3 (en) 4,5-diaryl oxazole derivatives and pharmaceutical compositions containing them
HUP9601285A3 (en) Substituted n-(indole-2-carbonyl)-beta-alaninamides and derivatives and pharmaceutical compositions containing them
IL117349A0 (en) N-(3-benyofuranyl) urea-derivatives their preparation and pharmaceutical compositions containing them
IL122345A0 (en) Benzamide derivatives their use as vasopressin antagonists processes for the preparation thereof and pharmaceutical compositions containing the same
HUP9902138A3 (en) N-[4-(heteroarylmethyl)phenyl]-heteroarylamine derivatives, their preparation and pharmaceutical compositions containing them
IL117810A0 (en) N-substituted azaheterocyclic carboxylic compounds their preparation and pharmaceutical compositions containing them
CZ129596A3 (en) Oxazolidinone derivative, process of its preparation and pharmaceutical composition containing thereof
IL122705A0 (en) 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives their preparation and pharmaceutical compositions containing them
HUP9801880A3 (en) Novel cryptophycins, their use and pharmaceutical compositions containing them
IL117620A0 (en) Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
HUP0000960A3 (en) Spray-dried paroxetine hydrochloride, process for it's preparation,use of the compound and pharmaceutical compositions containing the same
IL117495A0 (en) Beta-alanine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
CA2220019A1 (en) Pharmaceutical composition containing tiagabine hydrochloride and the process for its preparation
IL117989A (en) N-(1-(3,5-bisfluoromethylbenzoyl)-2- benzyl-piperidin-4-YL)-4-oxo-4H-1- benzopyran-2 carboxamides their preparation and pharmaceutical compositions comprising them
HUP9901212A3 (en) N-[2-(3-alkoxy-phenoxy)-ethyl]-dialkylamine derivatives, pharmaceutical compositions containing the same and their use as local anaesthetics
HUP9901349A3 (en) Oxazolidinone derivatives, their preparation and pharmaceutical compositions containing these compounds
IL117224A (en) 1,2,5-thiadiazole derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines and antimigraine pharmaceutical compositions comprising them
IT1269508B (it) Procedimento per la preparazione di particelle lavorate a secco, particelle lavorate a secco cosi' ottenute e composizioni farmaceutiche contenenti le particelle
HUP0105426A3 (en) Derivatives of 3-(2-oxo-[1,3']bipyrrolidinyl-3-ylidenemethyl)-cephems and pharmaceutical compositions thereof
IL105774A (en) N-(substituted 2-pyridyl)-6-chloro-4-hydroxy-2-methyl-2h-thieno 2, 3-e9-1, 2-thiazine-3-carboxamide, 1, 1-dioxides their preparation and pharmaceutical compositions containing them
IL133826A0 (en) Enantiomers of 4-[[(cyanoimino) [(1,2,2-trimethylpropyl) amino] methyl]amino]benzonitrile and pharmaceutical compositions containing the same
HUP0000934A3 (en) 4-{2-[n-(3-phenoxy-2-hydroxy)propylamino]-ethyl}-anilide derivatives and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
RH1 Patent not in force